Advertisement
News
Advertisement

DispersinB Combination Wound Care Product Passes Skin Irritation Tests

Wed, 04/03/2013 - 8:03am
The Associated Press

Kane Biotech Inc. (TSX VENTURE: KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms is pleased to announce that the DispersinB-Gentamicin combination wound gel spray has passed the primary skin irritation tests. The purpose of the skin irritation test is to determine the dermal irritation potential of topical DispersinB-Gentamicin wound gel spray as required by the FDA for biocompatibility. The biocompatibility study was conducted on the combination of DispersinB antibiofilm enzyme and the broad-spectrum antibiotic Gentamicin.

The study was conducted in compliance with Good Laboratory Practices (GLP) and also in accordance with the International Organization of Standardization: Biological Evaluation of Medical Devices, Part 10: Test for Irritation and Sensitization. Based on the skin irritation index (PII) for the formulation, the irritation response was negligible, thus the DispersinB-Gentamicin wound gel spray does not cause dermal erythema or edema due to skin irritation.

Kane Biotech has two DispersinB-based wound gel spray formulations in development for the topical wound care market. The first product is the DispersinB-Gentamicin wound gel spray for topical wound care in both human and veterinary applications. DispersinB-antimicrobial combinations have shown to be effective against Methicillin-resistant Staphylococcus aureus (MRSA) and Methicillin-resistant Staphylococcus pseudintermedius (MRSP) associated with human and companion animal wound infections, respectively. The second wound care product is in collaborative development with the US Army Institute of Surgical Research for combat wound infections.

About Kane Biotech Inc.
Kane Biotech is a biotechnology company engaged in the development and commercialization of products that prevent and remove biofilms. Biofilms develop when bacteria and other microorganisms form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria become highly resistant to antibiotics, biocides, disinfectants, high temperatures and host immune responses. This resiliency contributes to human health problems such as recurrent urinary tract infections, medical device associated infections and tooth decay.

Kane Biotech uses patent protected technologies based on molecular mechanisms of biofilm formation/dispersal and methods for finding compounds that inhibit or disrupt biofilms. The Company has evidence that these technologies have potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications.

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading